Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir

Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them. Gilead's three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2T4VLp9
via IFTTT